MarginsXMarginsX
Home › Markets › Health Care › ELUT

Elutia Inc. (ELUT)

ELUT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.8229
+0.35% on the day
Market cap
$36.5M
Nano cap
Revenue · 2025
$12.3M
-15.0% on 2024
Net income · 2025
$53.4M
434.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1708527/000110465926027664/0001104659-26-027664-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerELUT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001708527
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$12.3M
Net income$53.4M
Operating income-$26.9M
Net margin434.2%
Operating margin-218.9%
Revenue growth-15.0%
Cash$36.4M
Total assets$62.4M
P/E (computed)0.7×
P/S (computed)3.0×

Warning signs

Cash runway
7.1 months
$29.1M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$237K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"In accordance with Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated finan"
10-Q 2026-11-10
Cash and burn$29.1M cash; operating cash flow -$12.3M a quarter.Report 2026-09-30
Shares outstanding44,397,650 (2026-11-06).Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-08-07
AuditorPricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $237K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.1M-$1.3M-$8.1M$29.1M$8.1M$17.0M10-Q 2026-11-10
Q2 2026
2026-06-30
$2.4M-$7.6M-$8.5M$19.9MNo debt tags$16.8M10-Q 2026-08-14
Q1 2026
2026-03-31
$3.1M-$7.5M-$7.8M$28.5MNo debt tags$17.1M10-Q 2026-05-15
Q4 2025
2025-12-31
$10.3M$70.8M-$24.8M$36.4MNo debt tags$16.9M10-K 2026-03-13
Q3 2025
2025-09-30
$944K-$3.9M-$2.9M$4.7M$31.1M$9.5M10-Q 2026-11-10
Q2 2025
2025-06-30
$2.7M-$9.6M-$8.2M$8.5M$28.9M$12.2M10-Q 2026-08-14
Q1 2025
2025-03-31
$3.0M-$3.9M-$8.9M$17.4M$26.8M$15.7M10-Q 2026-05-15
Q4 2024
2024-12-31
$2.8M-$9.1M-$12.3M$13.2M$25.1M$19.5M10-K 2026-03-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-05-08
Latest annual report10-K2026-03-13
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 378 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.0%
1 month+6.1%
3 months-4.7%
Year to date+18.3%
1 year+10.4%
From 52-week high-32.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
EXOZeXoZymes Inc.$3.99+4.18%$37.1M
CRBUCaribou Biosciences Inc.$0.3528-2.51%$38.1M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
TILInstil Bio Inc.$5.75-5.43%$39.0M
IMAImageneBio Inc.$3.20-7.78%$39.9M
LONALeonaBio Inc.$3.23-6.92%$30.4M
INMBINmune Bio Inc.$0.9464-9.87%$29.3M
CVMCel-Sci Corporation$1.66+29.69%$29.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier